Amarin Corporation plc: Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC

Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the CongressDUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc

Related Keywords

United States , Paris , France General , France , United Kingdom , Lebanon , Austria , United Arab Emirates , Dublin , Ireland , Canada , Germany , Denmark , New Jersey , Finland , Sweden , Switzerland , Great Britain , Scotland , Dennis Riedl , Mark Marmur , Preston Mason , Phillippe Gabriel Steg , Lisa Defrancesco , Samuelcr Sherratt , Elucida Research , Drug Administration , Harvard Medical School , Investor Relations Amarin Corporation , Nasdaq , Exchange Commission , Amarin Corporation , Corporate Communications , European Union , Grade Mineral Oil , Corn Oil , World Congress , Department Of Medicine , In Vitro Data , New Orleans , Original Research , Ischemic Heart Disease , Icosapent Ethyl , Patients With Recent Acute Coronary Syndrome , Heart Disease , Population Science , Modulated Expression , Proteins Linked , Platelet Activation , Vascular Endothelial Cells , Harvard Medical , Translational Science , Pharmaceutical Grade Mineral Oil , Eicosapentaenoic Acid , Docosahexaenoic Acid , Atherosclerosis In Vitro , Vascular Disease , Valvular Heart Disease , Special Topics Moderated Poster Theater , Acids In Vitro , United Arab , Great Britain Marketing Authorization , Private Securities Litigation Reform Act , Securities Act , Relations Amarin Corporation , Amarin , Corporation , Present , Data , Valuating , Vascepa , Vazkepa , Icosapent , Methyl ,